SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending after CEO Alex Karp's CNBC appearance highlighted AI weapons and defensive products. This coincides with major new partnerships with Nvidia for sovereign AI OS and Ondas for multi-domain intelligence platforms, driving community discussion on its critical and expanding role in defense and enterprise AI.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath (PATH) is trending following its strong earnings beat, first GAAP profitability, and a new substantial stock buyback, sparking community debate over conservative growth guidance versus perceived market manipulation by shorts and the potential for a 'Palantir moment' with government AI contracts.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending with high anticipation ahead of the upcoming OFC Conference, where it will showcase its advanced optical engines for AI applications in a significantly expanded booth. Community speculation about potential major partnerships, especially after Marvell's acquisition of a POET customer, is fueling a strong bullish sentiment across the heating photonics sector.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending as the community buzzes about the enrollment of the first patient in its Phase 2 trial for SLS009 in first-line AML, building on impressive early survival data. This catalyst, coupled with the nearing completion of the REGAL Phase 3 for GPS and a strengthened balance sheet from recent warrant exercises, amplifies discussions of the company as a multi-asset contender in AML with potential for strategic partnerships.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas (ONDS) is trending following a strategic partnership with Palantir and the acquisition of BIRD Aerosystems, which significantly expands its AI-enabled multi-domain defense capabilities and generates immense buzz about its future in the defense sector. While many in the community are bullish, anticipating a major short squeeze and substantial growth, others remain cautious, citing concerns over dilution and the stock's muted reaction to the otherwise significant news.

Himax Technologies, Inc. is a semiconductor solution provider dedicated to display imaging processing technologies. It operates through the Driver Integrated Circuit and Non-Driver Products segments. The company's products include display drivers, timing controllers, wafer level optics, video and display technology solutions, liquid crystal over silicon silicon, complementary metal-oxide semiconductor image sensor, and power integrated circuit. Its products used in TVs, laptops, monitors, mobile phones, tablets, digital cameras, car navigation, virtual reality (VR) devices and many other consumer electronics devices. Himax Technologies was founded by Biing Seng Wu and Jordan Wu on June 12, 2001 and is headquartered in Tainan, Taiwan.

Himax Technologies - ADR

Himax Technologies, Inc.

Himax Technologies is trending following a Hunterbrook article positioning it as a "stealth supplier" for NVIDIA's AI optics revolution and TSMC's CPO platform, sparking intense community debate between bullish long-term CPO potential and warnings of a pump and dump amid volatile trading.

Lightwave Logic, Inc. is a development stage company which engages in the commercialization of electro-optic photonic devices. The firm offers the P2ICTM technology platform which uses in-house proprietary organic polymers. Its products include electro-optical modulation devices and proprietary polymer photonic integrated circuits. The company was founded on June 24, 1997 and is headquartered in Englewood, CO.

Lightwave Logic Inc

Lightwave Logic is trending due to its newly announced development agreement with Tower Semiconductor, which the community widely interprets as a critical step toward integrating its advanced polymer modulators into the NVIDIA supply chain. This partnership is fueling immense investor optimism that validates LWLG's technology for the rapidly expanding AI and data center photonics market, signaling a path to significant commercial adoption and substantial growth.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is trending as escalating tensions and reported tanker attacks in the Strait of Hormuz fuel significant concerns over global oil supply, leading to a sharp community divide between bulls anticipating much higher prices and bears expecting a swift market correction despite strategic reserve releases.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

The SPDR S&P 500 ETF Trust is trending amidst escalating geopolitical tensions, driven by Iran's threats to keep the Strait of Hormuz closed and surging oil prices, sparking community debate over market manipulation and global economic stability.

Firefly Aerospace, Inc. engages in the design and manufacture of space launch vehicles. It offers Alpha, Beta, Gamma, and orbital transfer vehicles. The company was founded by Thomas E. Markusic, Mark Watt, and Max Polyakov in January 27, 2017 and is headquartered in Cedar Park, TX.

Firefly Aerospace Inc.

Firefly Aerospace is trending following its successful Alpha Flight 7 mission, which delivered a Lockheed Martin payload and validated Block II upgrades, sparking widespread bullish sentiment and discussions of a significant comeback for the commercial space company after prior setbacks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Altimmune Details Pemvidutide MASH Path: Breakthrough Therapy, FDA Feedback, Phase 3 Next Up

Altimmune (NASDAQ:ALT) executives highlighted recent clinical and regulatory milestones for pemvidutide and outlined plans to advance a Phase 3 program in metabolic dysfunction-associated...

Altimmune Details Pemvidutide Phase III MASH Plans, Breakthrough Status at Citizens Conference

Altimmune (NASDAQ:ALT) executives used a presentation at the Citizens Life Sciences Conference to outline recent clinical results and development plans for pemvidutide, the company's lead drug...

Altimmune (NASDAQ:ALT) CEO Jerome Benedict Durso Buys 20,000 Shares

Altimmune, Inc. (NASDAQ:ALT - Get Free Report) CEO Jerome Benedict Durso acquired 20,000 shares of the company's stock in a transaction on Friday, March 6th. The stock was bought at an average price...

Gregory Weaver Acquires 5,000 Shares of Altimmune (NASDAQ:ALT) Stock

Altimmune, Inc. (NASDAQ:ALT - Get Free Report) CFO Gregory Weaver acquired 5,000 shares of the company's stock in a transaction that occurred on Friday, March 6th. The shares were acquired at an...

Altimmune (NASDAQ:ALT) CEO Acquires $70,800.00 in Stock

Altimmune, Inc. (NASDAQ:ALT - Get Free Report) CEO Jerome Benedict Durso acquired 20,000 shares of the company's stock in a transaction on Friday, March 6th. The stock was acquired at an average...

Altimmune (NASDAQ:ALT) Rating Lowered to Sell at Wall Street Zen

Wall Street Zen lowered shares of Altimmune from a "hold" rating to a "sell" rating in a research report on Saturday...

Altimmune (NASDAQ:ALT) Price Target Cut to $13.00 by Analysts at B. Riley Financial

B. Riley Financial decreased their target price on shares of Altimmune from $18.00 to $13.00 and set a "buy" rating for the company in a research report on Friday...

Altimmune (NASDAQ:ALT) Posts Quarterly Earnings Results, Misses Expectations By $0.02 EPS

Altimmune (NASDAQ:ALT - Get Free Report) announced its earnings results on Thursday. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.02). The...

Altimmune Q4 Earnings Call Highlights

Altimmune (NASDAQ:ALT) executives used the company's year-end 2025 results call to outline preparations for a pivotal Phase 3 program for pemvidutide in metabolic dysfunction-associated...

<ul class="summary-bullets"><li>The company said that it had cash and cash equivalents of $340 million as of the end of February, which it deems sufficient to provide an operating runaway into 2028.&nbsp;</li><li>Altimmune has already agreed with the U.S. Food and Drug Administration on an upcoming MASH trial’s design.</li><li>Meanwhile, data from the company’s mid-stage trial of pemvidutide in Alcohol Use Disorder AUD is expected in the third quarter of 2026.</li></ul>Shares of Altimmune Inc (ALT) fell 9% on Thursday after the company reported a wider-than-expected fourth quarter loss.For Q4, the biopharmaceutical company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.altimmune.com/news-releases/news-release-details/altimmune-announces-fourth-quarter-and-full-year-2025-financial">reported </a>a net loss of $0.27 per share, compared to a net loss of $0.33 in the same period of 2024, but more than a Wall Street estimate of $0.24 per share.<h2 class="st-heading-2">Cash Position</h2>Altimmune said that it had cash and cash equivalents of $340 million as of the end of February, which it deems sufficient to provide an operating runaway into 2028 based on its current expectations for the timing of its late-stage trial in Metabolic Dysfunction-Associated Steatohepatitis.“Our intent is on having the cash resources necessary to execute the MASH phase 3 trial. We'll continue to be strategic and opportunistic in our approach to securing access to the forecasted capital needed to fund the phase 3, and we'll keep you updated on our progress,” CFO Greg Weaver said.Altimmune has already agreed with the U.S. Food and Drug Administration on the upcoming trial’s design. The global late-stage trial of pemvidutide in MASH is expected to evaluate multiple doses of the drug over a 52-week treatment period with biopsy-based endpoints to support potential accelerated approval.Meanwhile, data from the company’s mid-stage trial of pemvidutide in Alcohol Use Disorder AUD is expected in the third quarter of 2026. Pemvidutide is Altimmune’s lead candidate and has also been studied in the treatment of alcohol-associated liver disease.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around ALT stock rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume increased from ‘low’ to ‘normal’ levels.A Stocktwits user said they are buying the dip.<stembedurl>https://www.stocktwits.com/Corpkcots/message/646685890</stembedurl>Another user expressed disappointment over the earnings but voiced hopes for a buyout deal or partnership agreement for the company.<stembedurl>https://www.stocktwits.com/Damnthisappilosthistory/message/646685060</stembedurl>Yet another said that the company has a roadmap in place and is positioning itself for bigger opportunities ahead. “Short-term drops like this do not change the company’s long-term strategy,” they said.<stembedurl>https://www.stocktwits.com/Oziboz/message/646681100</stembedurl><a href="https://stocktwits.com/symbol/ALT">ALT stock</a> has dropped 32% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/paramount-skydance-ceo-david-ellison-says-wbd-deal-positions-it-to-compete-more-effectively-globally-report/cZdQDDQRI3k">Paramount Skydance CEO David Ellison Says WBD Deal Positions It To Compete More Effectively Globally: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Altimmune logo is seen displayed on the screen of the tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

ALT Stock Drops On Wider-Than-Expected Q4 Loss: Retail Voices Hopes For Deal To Alleviate Cash Concerns

CFO says company continues to be “strategic and opportunistic” in approach to securing capital needed for late-stage MASH trial.

Equity

CFO says company continues to be “strategic and opportunistic” in approach to securing capital needed for late-stage MASH trial.


Altimmune Inc

Barclays 28th Annual Global Healthcare Conference

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Investors eagerly await a potential Big Pharma partnership or acquisition to secure funding and de-risk Pemvidutide's Phase 3 development and commercialization.

Concerns about external market manipulation, coupled with significant share dilution from increased authorized shares and ATM offerings, are pressing down on the stock price.

Recent investor conferences and fireside chats are criticized for repeating old information and failing to deliver new catalysts or strategic updates, disappointing investors.

Discussions center on the strategic planning for the global Phase 3 MASH trial, including the timeline, funding, and alignment with regulatory agencies such as the FDA and EMA.

Current Price	$3.68
Prev Close	$3.80
Open	$3.75
Dividend Yield	0.00%
50-Day Moving Average	$4.47
Beta	1.32
Avg. Volume	3.17M
PE Ratio	-3.74

52-Week High	$7.73
52-Week Low	$2.90
Market Capitalization	$494.27M
EPS (Annual)	-$0.9999
Price to Book	1.87
Revenue Per Employee	$719.30

ALT
Altimmune Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ALT News

ALTAltimmune Inc